Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dates: 2006-2007
Funding: Actelion Pharmaceuticals Ltd
Collaborators: Neurovascular Research Unit, Nuffield Department of Surgery, University of Oxford;Oxford Radcliffe NHS Trust
Information: Oliver Rivero-Arias, Alastair Gray and Jane Wolstenholme

Aneurysmal subarachnoid haemorrhage (aSAH) is a significant cause of death and continuing disability in relatively young patients with an annual incidence of between 6 and 7 per 100,000 population in most western countries. The natural history of the disease is such that over 30% of patients will die within 24 hours of the bleed and a further 25-30% will succumb in the next four weeks without some form of surgical intervention.

The aim of this project was to estimate the annual and lifetime costs of patients with aSAH in the UK. In addition, estimates of life-years and quality-adjusted life years (QALYs) lost due to aSAH were calculated.

The output from this work has been submitted to a peer-review journal.


Rivero-Arias, O, Wolstenholme, J, Gray, A, Molyneux, AJ, Kerr, RSC, Yarnold, JA, and Sneade, M (2009). The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm Trial. J Neurol, 256(3):364-73.